In a report released today, Michael King from EF Hutton reiterated a Buy rating on Sonnet BioTherapeutics Holdings (SONN – Research Report), with a price target of $6.70. The company’s shares closed yesterday at $0.92.
According to TipRanks, King is a 4-star analyst with an average return of 5.3% and a 41.60% success rate. King covers the Healthcare sector, focusing on stocks such as Agenus, Regeneron, and Sonnet BioTherapeutics Holdings.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sonnet BioTherapeutics Holdings with a $6.70 average price target.
See Insiders’ Hot Stocks on TipRanks >>
SONN market cap is currently $18.61M and has a P/E ratio of -0.15.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sonnet BioTherapeutics (NASDAQ:SONN) is a clinical-stage biotechnology company that is focused on the development of drugs for the treatment of cancer.
Read More on SONN:
- Sonnet BioTherapeutics reports Q1 EPS (80c) vs. ($1.44) last year
- Sonnet BioTherapeutics $15M Secondary priced at $1.08
- Sonnet announces pricing of $15M underwritten public offering
- Sonnet completes two IND-enabling toxicology studies with SON-1210
- Sonnet BioTherapeutics files to sell common stock, warrants, no amount given
